IRIS
DE LUCA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.960
NA - Nord America 5.487
AS - Asia 4.012
SA - Sud America 872
Continente sconosciuto - Info sul continente non disponibili 420
AF - Africa 86
OC - Oceania 3
Totale 16.840
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.181
RU - Federazione Russa 2.777
SG - Singapore 1.321
CN - Cina 1.313
IT - Italia 936
BR - Brasile 719
RO - Romania 708
SE - Svezia 474
HK - Hong Kong 469
VN - Vietnam 363
DE - Germania 275
FR - Francia 204
CA - Canada 160
BD - Bangladesh 153
GB - Regno Unito 150
FI - Finlandia 108
IN - India 85
NL - Olanda 83
AR - Argentina 64
AT - Austria 58
MX - Messico 51
JP - Giappone 50
PL - Polonia 42
ZA - Sudafrica 35
ES - Italia 34
TR - Turchia 34
ID - Indonesia 31
PH - Filippine 28
IQ - Iraq 24
EC - Ecuador 22
JM - Giamaica 20
VE - Venezuela 20
CR - Costa Rica 19
CO - Colombia 18
PK - Pakistan 18
UA - Ucraina 17
LT - Lituania 16
AE - Emirati Arabi Uniti 14
MY - Malesia 14
UZ - Uzbekistan 14
IE - Irlanda 13
PY - Paraguay 13
EG - Egitto 12
NI - Nicaragua 12
HN - Honduras 11
KR - Corea 11
BE - Belgio 10
MA - Marocco 10
TN - Tunisia 10
NP - Nepal 9
SA - Arabia Saudita 8
CL - Cile 7
GR - Grecia 7
IR - Iran 7
PE - Perù 7
BH - Bahrain 6
NO - Norvegia 6
AZ - Azerbaigian 5
CH - Svizzera 5
GT - Guatemala 5
KZ - Kazakistan 5
LU - Lussemburgo 5
LV - Lettonia 5
MK - Macedonia 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
EE - Estonia 4
IL - Israele 4
KE - Kenya 4
LB - Libano 4
PR - Porto Rico 4
SV - El Salvador 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
DZ - Algeria 3
JO - Giordania 3
PT - Portogallo 3
TH - Thailandia 3
AO - Angola 2
BB - Barbados 2
BS - Bahamas 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CU - Cuba 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
EU - Europa 2
HR - Croazia 2
HU - Ungheria 2
KH - Cambogia 2
MN - Mongolia 2
OM - Oman 2
PS - Palestinian Territory 2
SN - Senegal 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
BN - Brunei Darussalam 1
BO - Bolivia 1
Totale 16.410
Salva come PNG Salva come JPEG
Città #
Dallas 1.119
Ashburn 696
Singapore 681
Moscow 551
San Jose 512
Hong Kong 457
Shanghai 258
Milan 251
Beijing 211
New York 196
Council Bluffs 185
Hefei 156
Lauterbourg 133
Ho Chi Minh City 129
Los Angeles 127
Phoenix 115
Santa Clara 108
Princeton 104
Lawrence 99
Munich 96
São Paulo 79
Rome 64
Boardman 63
Hanoi 62
Nuremberg 62
Helsinki 60
Orem 44
Atlanta 42
Denver 40
Tokyo 40
Chicago 38
Montreal 37
Warsaw 35
Frankfurt am Main 31
Johannesburg 29
Rio de Janeiro 29
Chennai 28
Miano 28
Seattle 27
Turku 27
Brooklyn 26
Da Nang 26
Guangzhou 26
Toronto 25
Mexico City 24
Buffalo 23
Cesano Boscone 23
Poplar 23
Stockholm 23
Houston 22
London 21
Naples 21
Lappeenranta 20
Boston 19
Falkenstein 19
Amsterdam 18
Haiphong 18
Ankara 17
Manchester 17
Vienna 17
Omaha 16
Mumbai 15
Newark 15
Tianjin 15
Shenzhen 13
The Dalles 13
Campinas 12
City of London 12
Las Vegas 12
New Delhi 12
Secaucus 12
Tashkent 12
Belo Horizonte 11
Brescia 11
Dublin 11
Hangzhou 11
Istanbul 11
Managua 11
San José 11
Verona 11
Brasília 10
Florence 10
North Bergen 10
Padua 10
Porto Alegre 10
San Francisco 10
Xi'an 10
Can Tho 9
Columbus 9
Makati City 9
Bologna 8
Brussels 8
Dhaka 8
Guayaquil 8
Kuala Lumpur 8
Miami 8
Pietra Ligure 8
Pune 8
Roubaix 8
Seongnam-si 8
Totale 7.901
Salva come PNG Salva come JPEG
Nome #
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 478
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy 459
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 402
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 361
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 292
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 245
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 222
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 195
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 192
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 191
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 178
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 166
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 165
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 157
B cells in systemic sclerosis: A possible target for therapy 151
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 149
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 145
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 144
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 143
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 143
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 139
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 139
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 135
Arrhythmias in Myocarditis: State of the Art 133
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 133
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 132
Pruritus characteristics in a large Italian cohort of psoriatic patients 132
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 130
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 130
Therapeutic strategies for primary heart involvement in systemic sclerosis 128
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 128
A Novel Histiocytosis With Synovial and Skin Involvement 124
Drug retention rates of biological agents in adult onset Still's disease 124
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 123
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 121
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 121
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 121
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 121
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 121
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 120
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 119
C3-glomerulopathy and MGUS: The skin beyond the kidney 118
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 118
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 116
Cardiovascular magnetic resonance parametric mapping in the risk stratification of patients affected by chronic myocarditis 115
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 114
Advances in potential targeted therapies for Erdheim-Chester disease 113
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 112
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 112
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 112
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 112
The spectrum of covid-19-associated myocarditis: A patient-tailored multidisciplinary approach 111
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 108
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 107
Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis 107
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 106
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 106
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 105
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 105
Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis 105
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 104
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 102
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 102
Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies 101
Pain and Frailty in Hospitalized Older Adults 101
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 101
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 101
Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report 100
Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias 100
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 99
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 99
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 96
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 96
Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis 96
Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study 95
Unraveling the Pathogenesis of Calcinosis in Systemic Sclerosis: A Molecular and Clinical Insight 94
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 94
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 94
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 93
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 93
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 92
The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry 89
MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION 89
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 89
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 87
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis 87
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis 87
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 87
Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review 84
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 84
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study 83
Corrigendum to “Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience” [Autoimmunity Reviews, Volume 20, Issue 12, December 2021, 102981](S1568997221002615)(10.1016/j.autrev.2021.102981) 82
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 82
Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation 82
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 80
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 80
Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst 80
Therapeutic strategies for virus-negative myocarditis: a comprehensive review 78
Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression 78
Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging 78
Totale 12.993
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.420
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022146 0 0 0 46 9 16 4 7 11 31 5 17
2022/2023784 250 176 55 4 16 97 40 72 35 11 15 13
2023/2024744 25 56 75 67 65 111 42 82 5 33 36 147
2024/20253.364 224 41 102 104 130 218 1.093 331 388 233 200 300
2025/20269.539 612 868 944 1.147 707 286 724 665 2.473 491 293 329
2026/20272.073 374 481 464 754 0 0 0 0 0 0 0 0
Totale 16.840